Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2015 09:00 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics to Present at 27th Annual ROTH Conference

BRISBANE, Calif., March 6, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the 27th Annual ROTH Conference at 12:30 p.m....
February 27, 2015 08:00 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Observes Rare Disease Day 2015

BRISBANE, Calif., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today joins with patients and their families, caregivers, researchers, the biopharmaceutical industry and...
February 26, 2015 16:05 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results

UCD Product Portfolio Generates $113.6 Million for Fiscal Year 2014 and $30.8 Million in Net Sales During the Fourth Quarter of 2014 -- Company Generates $31 Million in Operating Cash Flows in...
February 25, 2015 16:45 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics to Present at the Cowen and Company 35th Annual Health Care Conference

BRISBANE, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the Cowen and Company 35th Annual Health Care...
February 19, 2015 16:00 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results After Market on February 26, 2015

BRISBANE, Calif., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report fourth quarter and full year 2014 financial results after market...
February 17, 2015 01:00 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Enters Into Completion of Phase III Clinical Trial, Option and Mutual Release Agreement With Clal Biotechnology Industries and Yeda Research and Development Company

BRISBANE, Calif., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) ("Hyperion") today announced that it has amicably resolved its disputes, and entered into a completion of...
February 10, 2015 09:00 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Initiates Clinical Study to Further Evaluate RAVICTI(R) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders

BRISBANE, Calif., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the dosing of the first patient in its HPN-100-009 study in pediatric subjects under two...
February 04, 2015 16:00 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics to Present at the 2015 Leerink Global Healthcare Conference

BRISBANE, Calif., Feb. 4, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the company is scheduled to present at the 2015 Leerink Global Healthcare Conference...
January 12, 2015 09:25 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Announces Data Published in Genetics in Medicine Showing Blood Ammonia and Glutamine as Predictors of Hyperammonemic Crises in Patients With Urea Cycle Disorders

BRISBANE, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced the online publication in Genetics in Medicine of analyses from four short-term switchover...
December 18, 2014 16:05 ET | Source: Hyperion Therapeutics, Inc.

Hyperion Therapeutics Added to Nasdaq Biotechnology Index (NBI)

BRISBANE, Calif., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it has been selected for addition to the NASDAQ Biotechnology Index®...